Animal Cell Technology Unit, IBET, Apartado 12, P-2781-901 Oeiras, Portugal.
J Invertebr Pathol. 2011 Jul;107 Suppl:S42-8. doi: 10.1016/j.jip.2011.05.004.
Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells.
病毒样颗粒（VLPs）作为疫苗候选物具有巨大的潜力。这些创新的生物制药具有显著的优势，它们能够非常逼真地模拟实际病毒的三维结构，而不包含其衣壳内包装的病毒基因组。因此，与灭活或减毒活病毒疫苗相比，预计会有同样高效但更安全的预防措施。随着基于 VLP 的成功获批疫苗案例的出现，制药公司确实正在将资源重新用于开发此类产品。本文综述了使用昆虫细胞的杆状病毒表达载体系统大规模生产和纯化基于 VLP 的疫苗的当前选择和趋势。
